ASH: Sickle Cell Treatment Decisions In The Post-Oxbryta, Genetic Medicine Era

Patients Have One Less Option Than A Year Ago

 
• By Mandy Jackson
  
Hematologists at ASH lamented the loss of Oxbryta for sickle cell patients (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASH

More from Scrip